CPG
BIO icon

Cornerstone Planning Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cornerstone Planning Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45K Sell
8
-7
-47% -$1.99K ﹤0.01% 1269
2026
Q1 		$3.86K Hold
15
– – ﹤0.01% 1152
2025
Q4 		$4.5K Hold
15
– – ﹤0.01% 1016
2025
Q3 		$4.57K Hold
15
– – ﹤0.01% 976
2025
Q2 		$4.08K Sell
15
-15
-50% -$3.55K ﹤0.01% 774
2025
Q1 		$7.47K Buy
30
+10
+50% +$3.01K ﹤0.01% 634
2024
Q4 		$7.18K Sell
20
-1
-5% -$339 ﹤0.01% 501
2024
Q3 		$6.96K Sell
21
-7
-25% -$2.22K ﹤0.01% 496
2024
Q2 		$9.2K Sell
28
-4
-13% -$1.16K ﹤0.01% 458
2024
Q1 		$8.96K Buy
32
+6
+23% +$1.97K ﹤0.01% 427
2023
Q4 		$8.39K Sell
26
-1
-4% -$313 ﹤0.01% 459
2023
Q3 		$9.68K Sell
27
-5
-16% -$1.93K ﹤0.01% 429
2023
Q2 		$12.1K Buy
+32
New +$13K ﹤0.01% 577
2022
Q4 		$6.76K Buy
+15
New +$6.05K ﹤0.01% 765

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cornerstone Planning Group's BIO Position: Q2 2026 in Review

Cornerstone Planning Group reduced its Bio-Rad Laboratories Class A (BIO) stake by 47% in Q2 2026, selling an estimated $1.99K and leaving 8 shares worth $2.45K. The position accounts for ﹤0.01% of the portfolio, ranked #1269.

Cornerstone Planning Group first reported a position in BIO in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.1K in Q2 2023. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Cornerstone Planning Group held 8 shares of Bio-Rad Laboratories Class A worth $2.45K as of Q2 2026.
  • Cornerstone Planning Group sold 7 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.99K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1269 holding.
  • Cornerstone Planning Group first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and has held it in 14 quarters since.
  • Cornerstone Planning Group's Bio-Rad Laboratories Class A position peaked at $12.1K in Q2 2023.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.